Seqirus receives FDA approval for Afluria Quadrivalent (influenza vaccine) for people 18 years of age and older

29 August 2016 - Seqirus is shipping trivalent and quadrivalent formulations of Afluria in the 2016-2017 influenza season.

Seqirus announced today that the US FDA has approved Afluria Quadrivalent (influenza vaccine) for use in persons 18 years of age and older. Afluria Quadrivalent is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine.

Both Afluria Quadrivalent and Afluria (influenza vaccine) are available in the US for the 2016-2017 influenza season.

Read Seqirus press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , US , Vaccine , Influenza